Alzheimer's Amyloid Hypothesis Faces Scrutiny

Decades of Alzheimer's research focusing on the amyloid-beta protein may be misguided, as multiple studies have been retracted and drugs targeting this pathway have failed. The amyloid hypothesis, which posits that amyloid-beta accumulation causes memory loss, has been a dominant theory since the 1980s. Despite significant investment and research, including the controversial FDA approval of Biogen's aducanumab, clinical trials have consistently shown limited efficacy and significant side effects. This ongoing scientific re-evaluation suggests a potential shift in understanding the complex mechanisms underlying Alzheimer's disease.